Therapeutic use of aerosolized S-nitrosoglutathione in cystic fibrosis
AssigneesDuke University, University of Virginia Patent Foundation
InventorsBenjamin Gaston, Jonathan S. Stamler
Life of this patent
Estimating the term…
Abstract
The present invention is directed to the treatment of cystic fibrosis that involves the administration of a nitrosylating agent, such as S-nitrosoglutathione or ethyl nitrite.
Claims7
A method for treating cystic fibrosis, said method comprising the step of administering a therapeutically effective amount of a composition comprising S-nitrosoglutathione to a patient having cystic fibrosis, wherein the composition is formulated as a powder or an aerosol and administered to the nasal mucosa and osteomeatal complex.
A method for treating cystic fibrosis comprising the step of administering a composition comprising a nitrosylating agent and an inhibitor of an enzyme that catabolizes S-nitrosothiol to a patient having cystic fibrosis.
A method of enhancing the expression and maturation of CFTR, said method comprising contacting the respiratory epithelium with a composition comprising a nitrosylating agent.
A method for preventing cough, dyspnea and chronic bacterial infection in cystic fibrosis comprising the step of administering a therapeutically effective amount of a composition comprising S-nitrosoglutathione formulated as a powder or an aerosol to the nasal mucosa and osteomeatal complex of a patient having cystic fibrosis.
Dependencies are inferred from the claim text.